Advancing innovation in lymphoma

CALYM is a nonprofit research institute that offers a unique R&D approach in lymphoma treatments and diagnostics, spanning from new target identification to large international phase 3 clinical trials. To download the full article, please sign in.

Like Comment
Page of
Go to the profile of CALYM


CALYM is a nonprofit research institute with complementary expertise in lymphoma preclinical, translational and clinical research. CALYM includes a network of over 130 clinical investigation centers linked to the Lymphoma Study Association (LYSA), an international leader of lymphoma research with 750 member physicians and over 30 years of experience in the clinical and translational fields. The Lymphoma Academic Research Organisation (LYSARC) is a fully integrated academic clinical research organization and is the operational and contract body for CALYM’s clinical programs. There are also 13 CALYM research teams based at universities and hospitals across France working on the pathophysiology of normal and neoplastic lymphoid tissue and the discovery of new therapeutic targets and agents. The integrated expertise and competencies found within CALYM enable it to cover all stages of lymphoma R&D for therapeutics and biomarkers, from the identification of new biological targets through to phase 3 clinical trials and beyond. CALYM received accreditation as a ‘Carnot institute’ from the French Ministry for Higher Education and Research in 2011. The prestigious Carnot label is awarded to public/parapublic research institutes that combine scientific excellence with professionalism and are committed to fostering innovation with industry partners.

No comments yet.